The post-marketing safety of Esketamine among older adults(≥ 65): an real-world pharmacovigilance study.
BMC pharmacology & toxicology August 29, 2025 Bin Deng, Zhiwen Fu, Linjie Li et al. 3 citations
AIMS: This study aims to investigate the safety profile of Esketamine, with a particular focus on comparing adverse events (AEs) between adults (< 65 years) and older adults (≥ 65 years) using data from the FDA Adverse Event Reporting System (FAERS). METHODS: We conducted a comprehensive analysis of FAERS data from 2019 to 2024, identifying 6,452 Esketamine-related AE reports. After removing...